Welcome to our dedicated page for Pennant Group SEC filings (Ticker: PNTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering where to locate Medicare reimbursement details, occupancy percentages or executive stock sales hidden inside Pennant Group disclosures? Those data points are scattered across multi-section 10-Ks, dense 10-Qs and late-night 8-Ks. This page brings every Pennant Group SEC filing into one place and lets Stock Titan’s AI do the heavy lifting.
Skip the 200-page search. Our platform instantly converts raw documents into clear takeaways, turning “Pennant Group insider trading Form 4 transactions” and “Pennant Group quarterly earnings report 10-Q filing” into plain-English summaries. Want real-time alerts? New filings hit your dashboard seconds after EDGAR posts them—so you’ll see Pennant Group Form 4 insider transactions real-time before the market reacts.
- 10-K & 10-Q—Track segment EBITDA, payor mix and occupancy metrics with Pennant Group annual report 10-K simplified and Pennant Group earnings report filing analysis.
- 8-K—Material event updates such as hospice acquisitions or leadership changes, fully tagged for Pennant Group 8-K material events explained.
- Form 4—Follow Pennant Group executive stock transactions Form 4 and spot emerging patterns.
- DEF 14A—Review Pennant Group proxy statement executive compensation without wading through boilerplate.
Each filing comes with an AI-powered synopsis that highlights revenue drivers, regulatory risks and key footnotes—understanding Pennant Group SEC documents with AI becomes effortless. Real-time updates, historical archives and side-by-side comparisons give you the context you need to evaluate census trends or reimbursement rate shifts before making a decision.
Whether you’re monitoring cost-of-care pressures, analysing hospice margins or checking Pennant Group SEC filings explained simply, Stock Titan turns complex disclosure into actionable insight—no forensic accounting required.
The Pennant Group (PNTG) entered a material financing amendment. On November 3, 2025, the company added an incremental Term Loan A of $100,000,000 under its Amended and Restated Credit Agreement with Truist Bank and additional lenders.
The new term loans bear the same interest rate and have the same maturity date as the company’s revolving facility. Pennant used the proceeds to refinance a portion of outstanding revolver borrowings and to pay related fees and expenses, effectively shifting debt from revolving to term while keeping pricing and maturity aligned.
The credit facility includes customary representations and covenants, including financial tests based on the Leverage Ratio and the Interest/Rent Coverage Ratio, and limits on additional indebtedness, liens, significant corporate changes, dispositions, and restricted payments. Standard events of default apply, including payment defaults, certain healthcare law violations, change in control, bankruptcy, and other operational covenants; if uncured, lenders may accelerate the debt.
The Pennant Group (PNTG) reported third‑quarter 2025 results with revenue of $229.0 million versus $180.7 million a year ago. Income from operations was $10.2 million compared to $10.8 million, and net income attributable to the company was $6.1 million versus $6.2 million. Diluted EPS was $0.17 versus $0.20.
Home Health and Hospice revenue reached $173.5 million and Senior Living $53.9 million. Segment Adjusted EBITDAR from Operations improved to $44.4 million, led by $29.1 million in Home Health and Hospice and $15.3 million in Senior Living. Year to date, operating cash flow was $27.3 million.
The company expanded through acquisitions in 2025, including part two of Signature Group (contributing $48.8 million revenue and $8.9 million operating income year to date) and additional home health deals. Cash was $2.3 million, long‑term debt was $26.0 million under the revolving credit facility, and total assets were $753.6 million. As of November 3, 2025, 34,593,720 common shares were outstanding. Subsequent to quarter end, Pennant closed a $146.5 million acquisition of home health, hospice, and home care locations and added a $100 million incremental term loan under its credit agreement.
The Pennant Group (PNTG) furnished an update on its third‑quarter performance. On November 5, 2025, the company issued a press release reporting financial results for the quarter ended September 30, 2025, and made the release available as Exhibit 99.1. The company also plans to post an updated investor presentation on its website for upcoming meetings. The information under Items 2.02 and 7.01, including Exhibit 99.1, was furnished and is not deemed filed or incorporated by reference except as specifically stated.
Pennant Group (PNTG)1,900 shares of common stock on 10/15/2025 at $0, indicating an award rather than an open-market purchase. According to the footnote, these shares vest in three annual installments beginning October 15, 2026.
Following this grant, the director beneficially owns 38,350 shares, held directly.
The Pennant Group (PNTG) director Christopher R. Christensen reported an award of 1,900 shares of common stock on October 15, 2025 at $0. The shares vest in three annual installments beginning October 15, 2026.
Following the transaction, he directly owned 140,291 shares and indirectly held 623,347 shares. Indirect holdings include shares held by Hobble Creek Investments, LLC, a 2020 irrevocable trust, his spouse, and shares held by his former spouse as custodian for their minor children.
Pennant Group (PNTG) director reported an equity award. On 10/15/2025, the reporting person acquired 1,900 shares of common stock at a reported price of $0. Following the transaction, the individual beneficially owns 96,799 shares, held directly.
The filing states these shares vest in three annual installments beginning October 15, 2026. This is a routine director equity grant and does not reflect an open‑market purchase.
Pennant Group (PNTG) reported an insider equity transaction by a director. On 10/15/2025, the reporting person acquired 1,900 shares of common stock at $0 per share, bringing total beneficial ownership to 224,664 shares, held directly.
The filing notes these shares vest in three annual installments beginning October 15, 2026.
Pennant Group (PNTG) reported an insider equity transaction by a director on 10/15/2025. The filing shows an acquisition of 1,900 common shares at $0, with a footnote stating these shares vest in three annual installments beginning October 15, 2026. Following the transaction, the director beneficially owns 168,865 shares directly and 2,700 shares indirectly through the Nackel Family Trust, over which the director and spouse share voting and investment power.
Pennant Group (PNTG) reported an insider transaction by a director on October 15, 2025. The director acquired 1,900 shares of common stock at a reported price of $0, bringing beneficial ownership to 31,600 shares, held directly.
The filing notes these shares vest in three annual installments beginning October 15, 2026. This appears to be a routine equity award reflecting standard director compensation practices and does not change control.
Pennant Group (PNTG) reported an insider equity grant. A director acquired 2,400 shares of common stock on 10/15/2025 (transaction code A, award at $0), with these shares vesting in three annual installments beginning October 15, 2026. Following the transaction, the director beneficially owns 51,735 shares, held directly.
FAQ
What is the current stock price of Pennant Group (PNTG)?
What is the market cap of Pennant Group (PNTG)?
